Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Anjie Biomedical Technology

Main focus: Next generation CAR-T cells

Company stage: Clinical

Diseases: Solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Guanzhou, China

Anjie Biomedical Technology develops next generation CAR-T cells for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its CAR-T cell products, in order to optimise efficacy and safety.


HashtagAnjie Biomedical Technology Co., Ltd

Company: Anjie Biomedical Technology
Search CRISPR Medicine